Mostrar el registro sencillo del ítem

dc.contributor.authorPorcuna, Jesus 
dc.contributor.authorMínguez-Martínez, Jorge
dc.contributor.authorRicote, Mercedes 
dc.date.accessioned2022-03-03T09:39:55Z
dc.date.available2022-03-03T09:39:55Z
dc.date.issued2021-09-30
dc.identifier.citationInt J Mol Sci. 2021 Oct; 22(19): 10573es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13712
dc.description.abstractPeroxisome proliferator-activated receptors (PPARs) are ligand-modulated nuclear receptors that play pivotal roles in nutrient sensing, metabolism, and lipid-related processes. Correct control of their target genes requires tight regulation of the expression of different PPAR isoforms in each tissue, and the dysregulation of PPAR-dependent transcriptional programs is linked to disorders, such as metabolic and immune diseases or cancer. Several PPAR regulators and PPAR-regulated factors are epigenetic effectors, including non-coding RNAs, epigenetic enzymes, histone modifiers, and DNA methyltransferases. In this review, we examine advances in PPARα and PPARγ-related epigenetic regulation in metabolic disorders, including obesity and diabetes, immune disorders, such as sclerosis and lupus, and a variety of cancers, providing new insights into the possible therapeutic exploitation of PPAR epigenetic modulation.es_ES
dc.description.sponsorshipThis research was funded by the Ministerio de Ciencia, Innovacion y Universidades (MCNU) (SAF2017-90604-REDT-NurCaMeIn, RTI2018-095928-BI00) and the Comunidad de Madrid (MOIR-B2017/BMD-3684) to MR; the MCNU fellowships to JP (FPU17/01731) and to JM-M (PRE2019-087964). The CNIC is supported by the MCNU and the Pro CNIC Foundation.es_ES
dc.language.isoenges_ES
dc.publisherMDPI es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.meshEpigenesis, Genetices_ES
dc.subject.meshAnimals es_ES
dc.subject.meshDNA Methylation es_ES
dc.subject.meshGene Expression Regulation es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmune System Diseases es_ES
dc.subject.meshMetabolic Diseases es_ES
dc.subject.meshNeoplasms es_ES
dc.subject.meshPPAR alpha es_ES
dc.subject.meshPPAR gamma es_ES
dc.titleThe PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorderses_ES
dc.title.alternativeThe PPAR alpha and PPAR gamma Epigenetic Landscape in Cancer and Immune and Metabolic Disorderses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial 4.0 Internacional*
dc.identifier.pubmedID34638914es_ES
dc.format.volume22es_ES
dc.format.number19es_ES
dc.format.page10573es_ES
dc.identifier.doi10.3390/ijms221910573es_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1422-0067es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/22/19/10573/htmes_ES
dc.identifier.journalInternational journal of molecular scienceses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Señalización de los Receptores Nucleareses_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SAF2017-90604-REDT-NurCaMeInes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-095928-BI00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MOIR-B2017/BMD-3684es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU17/01731es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PRE2019-087964es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial 4.0 Internacional